GSFC Q1FY27: consolidated PAT +14% YoY to ₹158.5 Cr, fertilizer margins compress
PAT +14.39% YoY · revenue +64.03% · margins compressing
₹3,583.15 Cr
+64.03% YoY
₹158.54 Cr
+14.39% YoY
4.38%
-1.9pp YoY
₹3.98
GSFC's consolidated Q1 FY27 (quarter ended June 30, 2026) revenue rose 64.0% YoY to ₹3,583.15 Cr, but consolidated PAT grew only 14.4% YoY to ₹158.54 Cr (EPS ₹3.98 vs ₹3.48), with net profit margin compressing to roughly 4.4% from about 6.2% a year ago. The QoQ swing looks dramatic — PAT up over 3x from ₹52.14 Cr in Q4 FY26 — but Q1 is the seasonally heavier Kharif-linked fertilizer quarter, so the QoQ jump is a seasonality artifact rather than a trend and should not be read as momentum.
Q1 FY-2027 vs prior quarters
The divergence between revenue and profit growth is squarely a fertilizer-segment story: fertilizer segment revenue jumped 80.7% YoY to ₹2,948.51 Cr on higher realizations/volumes, yet segment profit before tax and finance costs actually fell 13.2% YoY to ₹118.41 Cr, as cost of materials consumed rose 91.6% YoY (₹2,409 Cr) and purchases of stock-in-trade rose 170% YoY (₹1,068 Cr) — input costs outran topline growth. Offsetting this, the Industrial Products segment was the quarter's real profit engine: revenue up 14.8% YoY to ₹634.64 Cr but segment profit up 369% YoY to ₹115.93 Cr, consistent with the caprolactam-benzene spread improvement management had flagged. Standalone PAT of ₹161.11 Cr (+15.0% YoY, EPS ₹4.04) tracked the consolidated print closely.
The stock went into the print at ₹160.69, up 0.9% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
Management expressed confidence in continued strong performance, particularly in the Industrial Product segment, citing improving caprolactam-benzene spreads. For the fertilizer segment, while raw material markets remain unsettled due to geopolitical factors, government support through revised NBS rates is expected to
— This quarter: met
This outcome matches the company's prior (Q4 FY26 concall) guidance almost exactly: management had said any fertilizer-segment margin shortfall from unsettled raw-material markets would be offset by industrial-segment strength tied to caprolactam-benzene spreads — that is precisely what played out, so the print should be read as guidance met rather than a beat or miss. No analyst consensus estimates for this print turned up in search, so a street comparison is unavailable; the filing itself carries no MD&A commentary beyond the numbers. Corporate developments this quarter include the resignation of ED (Agri Business, HR & IR) S. V. Varma and a planned reduction of GSFC's stake in subsidiary GPLCL to 11% — neither materially affects this quarter's numbers. Other Comprehensive Income of ₹726.65 Cr (largely fair-value gains on the company's investment book) lifted total comprehensive income to ₹780.90 Cr, well above reported PAT, but this is a mark-to-market item sitting outside operating performance.
W1
Fertilizer segment margin recovery — segment profit fell 13.2% YoY on rising input costs; watch whether cost of materials (+91.6% YoY) moderates next quarter
W2
Caprolactam-benzene spread durability — Industrial Products segment profit of ₹115.93 Cr (+369% YoY) is highly spread-dependent
W3
GPLCL stake reduction to 11% (announced Jun 26, 2026) — watch for consolidation/scope impact in coming quarters
Consolidated PBT of 205.14 includes 3.11 Cr share of associate profit over the 202.03 pre-associate figure; PAT of 158.54 splits 158.53 to owners and 0.01 to NCI. Large OCI gain of 726.65 Cr (investment fair-value marks) sits outside PAT. Clean scan, all totals tie exactly.
Informational and educational content only. Not investment advice.